Overview
- Envudeucitinib met co‑primary endpoints in two ONWARD trials, with an average 74% of patients achieving PASI75 and 59% rated clear or almost clear by sPGA at four months.
- Responses deepened through Week 24, with about 65% reaching PASI90 and more than 40% achieving PASI100, with separation from placebo seen by Week 4.
- Treatment was generally well tolerated through 24 weeks, with mostly mild to moderate adverse events such as headaches, nasopharyngitis, upper respiratory infections, and acne.
- Each study showed superior skin‑clearance outcomes versus apremilast at Week 24 across PASI measures.
- Alumis announced a proposed $175 million underwritten public offering following the data release, while shares more than doubled in Tuesday trading, and the company expects lupus Phase 2b topline results in Q3 2026.